Homocysteine: Chemistry, metabolism and roles in pathophysiology processes;Homocistein: Hemija, metabolizam i uloga u patofiziološkim procesima

Jugoslovenska Medicinska Biokemija

Volumn 22, Issue 2, 2003, Pages 127-140

  Mirković, Duško ^a   Majkić Singh, Nada ^b   Ignjatović, Svetlana ^b  

^a Institut za Medicinsku Biohemiju   (Yugoslavia)

^b NONE

Author keywords

Coronary artery disease; Homocysteine; Hyperhomocysteinemia; Risk factor

Indexed keywords

CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

AMINO ACID ANALYSIS; AMINO ACID METABOLISM; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; HOMOCYSTEINE URINE LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MENTAL DEFICIENCY; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; THROMBOSIS; VASCULAR ENDOTHELIUM;

THROMBUS;

EID: 0037785270     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0302127M     Document Type: Conference Paper

References (74)

1. Roberts JT, Caserio MC. Basic Principals of Organic Chemistry. New York and Amsterdam: WA. Benjamen, Inc., 1965; 747-58.
2. Streitweisser A, Heathcock CH. Introduction to Organic Chemistry. New York: Macmillan Publishing Co., 1985; 756-60.
3. Jakoby WB, Griffith OW. Methods in Enzimology. Orlando, FL: Academic Press, 1987; 366-76.
4. Jocelyn PC. The Biochemistry of the SH Group. London: Academic Press, 1972.
5. Friedman M. The Chemistry and Biochemistry of the Sulfhydryl Group in Amino Acids, Peptids, and Proteins. Pergamon Press, 1973.
6. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1; 228-37.
7. Ueland PM, Refsum H, Brattstrom L. Atreriosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function. New York: Marcel Decker, 1992; 183-96.
8. Mudd SH, Levy HL, Skovby F. The Methabolic Basis of Inherited Diseases. New York: Mc-Grow-Hill, 1989; 693-734.
9. Mudd SH, Pool JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975; 24: 721-35.
10. Backlund PS, Smith RA. Metionine Synthesis from 5-methylthioadenosine in rat liver. J Biol Chem 1981; 256: 1533-35.
11. de la Haba G, Cantoni GL. The enzymatic synthesis from S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem 1959; 234: 603-8.
12. Malinow MR, Axthelm MK, Meredith MJ, Macdonald NA, Upson BM. Synthesis and trannssulfuration of homocysteine in blood. J Lab Clin Med 1994; 123; 421-9:
13. Wang J, Dudman NPM, Wilcken DEL, Lynch JF. Homocysteine catabolism: Levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease. Arteriosclerosis 1992; 97: 97-106.
14. McCully KS. Homocysteine theory of arteriosclerosis: Development and current status. Athreroscl rev 1983; 11: 157-246.
15. Wagner C, Briggs WY, Cook RJ. Inhibition of glycine N-methyltransferase by folate derivatives: Implications for the regulation of methyl group metabolism. Biochem Biophys Res Commun 1985; 127: 746-52.
16. Jencks DA, Matthews RG. Allosteric inhibition of methylentetrahydrofolate reductase by adenisylmethionine. J Biol Chem 1987; 262: 2485-93.
17. McKeever MP, Weir DG, Molloy A, Scott JM. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 1991; 81: 551-6.
18. Goyette P, Summer JS, Milos R, Duncan AMV, Rosenblatt DS, Matthews RG, Rozen R. Human methylentetrahydrofolate reductase; isolation of c-DNA mapping and mutation identification. Nature Genet 1994; 7: 195-200.
19. Finkelstain JD. The regulation of homocysteine metabolism. In: Graham I, Refsum H, Rosenberg IH, Ueland PM, eds. Homocysteine Metabolism: From Basic Science to Clinical Medicine. Boston: Kluwer Academic Publishers, 1997; 3-9.
20. Refsum H, Guttormsen AB, Fiskerstrand T, Ueland PM. On the formation and fate of total plasma homocysteine. In: Graham 1, Refsum H, Rosenberg IH, Ueland PM, eds. Homocysteine Metabolism: From Basic Science to Clinical Medicine. Boston: Kluwer Academic Publishers, 1997; 23-9.
21. Jurgen Geisel, Ilona Zimbelmqann, Heike Schorr, Jean-Pierre Knapp, Marion Bodis, Ulrich Hubner and Wolfgang Hermann. Genetic Defects as Important Factors for Moderate Hyperhomocysteinemia. Clin Chem Lab Med 2001; 39: 688-704.
22. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA. A candidate genetic risk factor vascular disease: a common mutation in methylentetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
23. Klujtmans Laj, Van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylentetrahydrofolate reductase gene is a genetic risk factor for cardiovascular di-sease. Am J Hum Genet 1996; 58: 35-41.
24. Mudd SH, Levy HL, Skovby F. The Metabolic Basis of Inherited Disease. New York; Mc Graw-Hill, 1989; 693-734.
25. McDonald MC, Dempsey GI, Nassar BA. Relation of a Common Mutation in Methylenetetrahydrofolate Reductaze to Plasma Homocysteine and Early Onset Coronary Artery Disease. Clin Biochem 1998; 31: 95-100.
26. Kang SS, Wong PWK, Zhou J, Sora J, Ruggie N, Grevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1991; 37: 611-13.
27. Mudd SH, Levy HL, Skovby F. Disorders of Trans-sulfuration. In: The Metabolic Basis of Inherited Disease, 6th edition, Scriver CR, Beaudet AT, Sly WS, and Valle D, eds, McGraw-Hill, 1989; 2049-64.
28. Carson NAJ, Cushword DC, Dent CE et al. Homocysteinuria: A new inborn error of metabolism with mental deficiency. Arch Dis Child 1963; 38: 425-36.
29. Mudd SH, Skovby F, Levy HL et al. The natural history of homocysteinutia due to β-synthase deficiency. Am J Hum Genet 1985; 37: 26-31.
30. Rima R. Homocysteine Metabolism: From Basic Science to Clinical Medicine: Boston: Kluwer Academic Publisher, 1997; 37-42.
31. Soo-Sang K, Edward LP, Myunghee HK, Neal R. Homocysteine Metabolism From Basic Scienceto Clinical Medicine. Boston: Kluwer Academic, 1997; 43-9.
32. Skovby F. Homocystinuria. Clinical, biochemical and genetic aspects of cystathionine beta-synthase and its deficiency in man. Acta Paediatr Scand 1985; 321: 1-21.
33. Mudd SH, Edwards WA, Loeb PM, Brown MS, Laster L. Homocysteinuria due to cystatione synthase deficiency; The effect of Pyridoxine. J Clin Invest 1970; 49: 176-273.
34. Ubbink JB, Vermaak WJ, van der Merwe, Becker PJ. The effect of the blood sample, aging and food consumption on plasma total homocysteine levels. Clin Chem Acta 1992; 207: 119-28.
35. Guttormsen AB, Schneede J., Fisherstrand T, Ueland PM, Refsum HM. Plasma concetration of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994; 124: 1934-41.
36. Guttormsen AB, Mansoor AM, Fiskerstrand T, Ueland PM, Refsum H. Assesment of homocysteine status. J Inher Metab Dis 1997; 20: 286-94.
37. Brattstrom L, Lindgren A, Israelson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236: 633-41.
38. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Jl J, Otto MJ, Taylor ML. Rapid HPLC Determination of Total Homocysteine and Other Thiols in Serum and Plasma: Sex Differences and Correlation with and Folate Concentrations in Healthy Subjects. Clin Chem 1994; 40: 873-81.
39. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid-an inno-cuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1998; 48: 215-21.
40. Hultberg B, Agardh CD, Agardh E, Lovestami-Adrian M. Poor metabolic folate deficiency are associated with increasing levels og plasma homocysteine in insulin-dependent diabettes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 1997; 57: 595-600.
41. Hulberg B, Agardh E, Andersson A. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopapathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277-82.
42. Bertino JR. Ode de methotrxate. J Cli Oncol. 1993; 11: 5-14. Allegrac CH, Fine RL, Drake JC, Chabner BA. The effect of metotrerexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1987; 261: 6478-85.
43. Bertino JR. Ode de methotrxate. J Cli Oncol. 1993; 11: 5-14. Allegrac CH, Fine RL, Drake JC, Chabner BA. The effect of metotrerexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1987; 261: 6478-85.
44. Kobblin DD. Toxicity of nitrous oxide. In: Rice SA, Fish KJ. Anestetic Toxity. Ravev Press 1994, 135-55.
45. Rasmussen K, Moller J. Total homocysteine in clinical practice. Ann Clin Biochem 2000; 37: 627-48.
46. Daly D, Miller LW, Nadeau MR, Selhud J. The effect of acute L-dopa administration on plasma homocysteine levels in folate repleted and depleted rats. FASEB J 1989; 43: 77-90.
47. Velja Milatovic, and Marius J. van der Mooren. Homocysteine in Postmenopausal Women and the Importance of Hormone Replacement Therapy. Clin Chem Lab Med 2001; 39 (8): 764-7.
48. 12 and folic acid, proteins and fine structure of the liver. Epilepsia 1987; 28: 147-59.
49. Blankenhorn DH, Malinow MR, Mack WJ. Colestipol plus niacin therapy elevates plasma homocysteine levels. Coron Art Dis 1991; 2: 357-60.
50. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993; 17: 687-9.
51. Rasmussen K, Moller J. Total homocysteine in clinical practice. Ann Clin Biochem 2000; 37: 627-48.
52. Hultberg B, Andersson A, Masson P, Larson M, Tunek A. Plasma homovcysteine and thiol compound fractions after oral administration of n-acetylcysteine. Scand J Clin Lab Invest 1994; 54: 417-22.
53. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT. Variability and determinanys of total homocysteine concentrations in plasma in an elderly population. Clin Chem 1998; 44: 102-7.
54. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-51.
55. Moller J, Rasmussen K. Homocysteine in plasma: stabilisation of blood samples with fluoride. Clin Chem 1995; 41: 759-68.
56. Probst R, Brtandl R, Blumke M, Neumeier D. Stabilization of homocysteine concentration in whole blood. Clin Chem 1998; 44: 1567-9.
57. Michel G, Staub U, Schroeder G, Shih J, and the International Hcy group. Determination of Homocysteine Reference Intervals: Data From the European Automated FPIA Study. Clin Lab 1999; 45: 651-6.
58. Mansoor MA, Svardal AM, Schneede J, Ueland PM. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionin loading in healthy man. Clin Chem 1992; 38: 1316-21.
59. Bostom AG, Roubenoff R, Dellaripa P, Nadeau MR, Sutherland p, Wilson PW. Validation of abbreviated oral methionine-loading test. Clin Chem 1995; 41: 948-9.
60. Matthias Nauck, Emmanuel Bisse, Markus Nauck and Heinrich Wieland. Preanalytical Conditions Affecting the Determination of the Plasma Homocysteine Concentracion. Clin Chem Lab Med 2001; 39: 675-680.
61. Graeme J Hankey, John W Eikelboom. Homocysteine and vascular disease. The Lancet 1999; 354: 407-13.
62. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 43: 1279-98.
63. Pietrzik K, Bronstrup A. Causes and consequences of hyperhomocysteinemia. Int J vitam Nutr Res 1997; 67: 389-95.
64. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
65. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williamss RR. Plasma homocysteine as a risk factor for early familial coronary artery disease. Clin Chem 1994; 40: 552-61.
66. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71: 227-33.
67. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-13.
68. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M. Sylvia de Jong. Hyperhomocysteinemia in Patients with Peripheral Arterial Occlusive Disease. Clin Che Lab Med 2001; 39: 714-6.
69. Ubbink JB, Vermaak WJ, Delport R, van der Merwe, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African black against coronary heart disease. Am J Clin Nutr 1995; 62: 802-8.
70. Vermaak WJ, Ubbink JB, Delport R, Becker PJ, Bissport SH, Ungerer JP. Ethnic Immunity to coronary Heart Disease. Atherosclerosis 1991; 89: 155-62.
71. Obeid OA, Mannan N, Perry G, Iles RA, Boucher BJ. Homocysteine in healty east London Bangladeshis. Lancet 1998; 352: 1829-30.
72. den Heijer M, Keijzer MBAJ. Hyperhomocysteinemia as a risk Factor for Venous Thrombosis. Clin Chem Lab Med 2001; 39 (8): 710 -3.
73. Mirković D. Prospektivna studija o statusu homocisteina kod karakterističnih grupa pacijenata. Jug Med Biohem 2002; 2: 114.
74. Mirković D. »Potencijalni hemizmi uticaja homocisteina na nastanak bolesti vaskularnog sistema«. Peta godišnja naučna konferencija »Profesor Ivan Berkes«. 22. novembra 2002 Beograd.